Efficacy and Safety of Stealth Liposomal Doxorubicin in AIDS-Related Kaposi's Sarcoma
Author Information
Author(s): F-D Goebel, D Goldstein, M Goos, H Jablonowski, JS Stewart
Hypothesis
The study aims to evaluate the efficacy and safety of Stealth liposomal doxorubicin (SL-DOX) in treating moderate to severe AIDS-related Kaposi's sarcoma.
Conclusion
SL-DOX shows substantial activity in treating AIDS-related Kaposi's sarcoma with manageable toxicity.
Supporting Evidence
- 15 patients (6.3%) had a complete response to SL-DOX.
- 177 patients (74.4%) had a partial response.
- 44 patients (18.5%) had stable disease.
- Neutropenia occurred in 57.1% of patients for whom data were available.
Takeaway
This study tested a special type of medicine called SL-DOX to help people with a serious skin cancer related to AIDS, and it worked well for many patients.
Methodology
Patients were treated biweekly with varying doses of SL-DOX, and tumor response was assessed using AIDS Clinical Trials Group criteria.
Limitations
The study primarily included severely immunocompromised patients, which may limit the generalizability of the results.
Participant Demographics
{"age_mean":39.1,"male_percentage":98.0,"race":{"caucasian_percentage":93.1,"non_caucasian_percentage":6.9},"risk_factors":{"homosexuality_percentage":85.0,"IVDA_percentage":4.0},"CD4_count_median":30.5}
Statistical Information
Confidence Interval
76% to 86%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website